Physician profile
Alex Chai
NPI 1316035819
$3,180.36
in general payments reported to CMS, 2019-2025
16 companies · $602 in 2025
The $602 reported for 2025 was more than what 77% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $108 · 2020: $121 · 2021: $375 · 2022: $440 · 2023: $748 · 2024: $785 · 2025: $602.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,135.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,135.41 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $582.68 | 2020-2025 | Ubrelvy, Qulipta, Vraylar |
| Pfizer INC. | $436.47 | 2021-2025 | |
| Lilly USA, LLC | $411.53 | 2021-2025 | Mounjaro, Zepbound, Trulicity |
| Bayer Healthcare Pharmaceuticals INC. | $372.05 | 2022-2025 | |
| Novo Nordisk INC | $335.01 | 2022-2025 | Ozempic, Wegovy, Rybelsus |
| Inari Medical, INC. | $314.13 | 2023-2024 | Ct Thrombectomy System Kit, Flowtriever Catheter, S |
| Amgen INC. | $216.75 | 2019-2025 | Otezla, Repatha, Repatha |
| Novartis Pharmaceuticals Corporation | $136.61 | 2019-2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $97.41 | 2024-2025 | Jardiance |
| Janssen Pharmaceuticals, INC | $96.79 | 2023-2024 | Xarelto |
| Abbott Laboratories | $49.52 | 2025 | Freestyle Libre 3 |
| Amarin Pharma, INC. | $45.26 | 2021 | |
| Alexion Pharmaceuticals, INC. | $30.77 | 2021 | |
| Astellas Pharma US INC | $21.86 | 2019 | |
| Mannkind Corporation | $19.77 | 2023 | Afrezza |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Dexcom, INC. | $13.75 | 2023 | Dexcom G6 Transmitter |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Alex Chai listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.